Skip to main content
. 2020 Jul 20;12(7):1967. doi: 10.3390/cancers12071967

Figure 2.

Figure 2

Kaplan-Meier estimates of the impact of intravenous (iv) central nervous system directed chemotherapy on survival among non-lymphopenic rituximab treated patients (A,B) and lymphopenic rituximab treated patients (C,D). An association to an improved progression free survival (PFS) and overall survival (OS) is seen only among non-lymphopenic patients (A,B).